5 assets in Krabbe Disease

Therapeutic assets addressing Krabbe Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Krabbe Disease	Masonic Cancer Center, University of Minnesota	P2/3	B (62)
Alemtuzumab Krabbe Disease	Masonic Cancer Center, University of Minnesota	P2	B (57)
Cald Hr-D Krabbe Disease	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Pbkr03 Krabbe Disease	Gemma Biotherapeutics	P1/2	CCC (48)
Duoc-01 Krabbe Disease	Joanne Kurtzberg, MD	P1	CC (43)